Webinaire

The new rules of procurement: From cost center to strategic growth engine

Procurement is under more pressure than ever, and it has a greater opportunity to create strategic value. Today’s procurement leaders are being asked to reduce costs, strengthen supply continuity, manage risk, improve supplier performance, and support business growth at the same time. As supply networks grow more complex and expectations continue to rise, procurement is taking on a broader role across the business. Join senior leaders from UCB Biopharma, Jazz Pharmaceuticals, and Cencora for a live webinar on Thursday, November 12th at 11am ET. Discover how forward-looking procurement organizations are responding to these pressures and redefining what leadership looks like in practice.

Key highlights

  • How leading organizations are measuring procurement success beyond cost savings
  • Practical ways to balance cost control with resilience and supply continuity
  • How to evaluate total business impact, not purchase price alone
  • Approaches to strengthening supplier partnerships and supplier ecosystem performance
  • The capabilities that are expected to shape future-ready procurement teams, including data, collaboration, risk management, and automation

Moderator:
Hugo Pessoa, Senior Director, Global Consulting Services, Global Strategic Accounts, Cencora

Speakers:
Gerardo Fuertes, Senior Director, Business Development, 3PL, Alloga Europe, Cencora
Mark Cawley, Associate Director, Research Procurement (Regulatory Affairs, PV and Medical Affairs), Jazz Pharmaceuticals
Baudoin Kopp, Global Category Lead, Supply Chain, CTS & Utilities, UCB Biopharma

Nous sommes là pour vous aider

Contactez notre équipe dès aujourd’hui pour en savoir plus sur la façon dont Cencora contribue à façonner l’avenir des soins de santé.

Ressources connexes

Infolettre

ETS trimestrielle automne 2026

Article

Collision entre la JCA de l’UE et la NPF américaine : La prochaine frontière mondiale de la tarification et du risque d’accès au marché

Article

L’avenir des soins gérés : Comment l’IA peut transformer les opérations pharmaceutiques d’ici 2030